Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study
Concomitant use of hormone therapy and antihypertensive therapy in elderly women is compelled by a high prevalence of breast cancer with hypertension [1] . However, very little is known about the possible interaction of combined treatment and older patients represent a high-risk group due to declining renal function and liver metabolism. Previous research into the effect of aromatase enzyme activity using angiotensin-converting enzyme (ACE) inhibitors has been predominantly carried out on animal models. ACE inhibitors have been shown to cause a decrease in 17 β-oestradiol production and an increase in androgen production, while angiotensin II (ANG II) causes an increase in 17 β-oestradiol production and a decrease in androgen levels. This analysis of aromatase enzyme activity has shown that the latter is positively regulated by ANG II and negatively by ACE. It can be concluded that ACE and ANG II activity independently modulate aromatase activity and this suggests a new physiological role for ACE and ANG II [2] .
In this study, we evaluated the pharmacokinetic interaction of combined treatment with anastrozole and quinapril in elderly women affected by breast cancer requiring hormonal treatment, and moderate hypertension. We enrolled five women affected by breast cancer and moderate hypertension (grade 2; WHO-ISH guidelines [3]), who had been free from treatment for 4 weeks, and five women with breast cancer without hypertension. The average age was 77 ± 7 years.
The following treatments were administered and blood samples collected. Group A: five patients were treated with anastrozole for at least 10 weeks; blood samples (6 ml of heparinized blood) were taken before starting treatment (time 0), and after 21, 28, 42, 56 and 70 days of therapy. Group B: five patients were treated with anastrozole for 10 weeks; after 4 weeks they received quinapril for 28 days; blood samples were taken at the same time as group A. Blood pressure was measured at the time of entry, before starting quinapril and twice a day during the 4 weeks of treatment with ACE inhibitor. Primary assessment was the steady-state plasma anastrozole concentrations following once-daily anastrozole alone or anastrozole plus quinapril. The evaluation of plasma anastrozole concentrations started after 21 days of drug administration, to ensure the steady-state had been obtained. Blood samples were taken from each patient 12 h after each dose of anastrozole: at days 21 and 28 for baseline measurements; days 42 and 56 for on-treatment measurements; and day 70 for post-treatment evaluation.
Anastrozole analysis in plasma was carried out according to the Bock et al. validated method of solvent extraction, capillary gas chromatography separation and electron capture detection [4] . The plasma levels of quinapril and of its active metabolite, quinaprilat, were determined according to the method of Hengy and Most [5] . Plasma levels of anastrozole and quinapril were analysed using validated methods. The sensitivity limit was ∼3 ng/ml.
Comparisons of the plasma anastrozole levels between the two groups were obtained through the non-parametric Mann-Whitney test. The mean plasma anastrozole concentration in group A was 59.2 ng/ml on day 21 and 62.6 ng/ml on day 56. For group B, the mean concentration was 49.43 ng/ml on day 21 and 49.80 ng/ml on day 56. None of the mean values were significant at a 5% confidence level (Table 1) .
In both groups of patients, the steady-state anastrozole concentrations remained similar during treatment with anastrozole 1 mg once daily, alone or in combination with quinapril; there were no statistically significant differences in plasma levels between patients who received anastrozole alone or in association with quinapril. Hypertension, monitored during the study period, was well controlled in all patients (Table 2 ).
In conclusion, these data show that the combination of quinapril and anastrozole can be safely and effectively administered to older patients with breast cancer and moderate hypertension. Also, the administration of quinapril to patients treated with anastrozole does not modify the plasma concentration of anastrozole and a dose modification is not required. 
Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL)
We read with interest the clinical cases describe by Minisini et al. and their review of the literature related to nail toxicity associated with taxane therapy [1] . Nail changes are reported with docetaxel given as 3-weekly or weekly schedules, and with weekly paclitaxel. The authors suggested that nail changes were based on taxane-induce vascular abnormalities (hematoma, hemorrhagic lesions) and neurotoxic damage (onycholysis). Previous reports focusing on onycholysis after prolonged weekly paclitaxel hypothesized direct toxicity to the nail bed, inhibition of angiogenesis, a possible role of ultra-violet light in nail damage, higher paclitaxel dose density and cumulative doses reached with weekly schedules [2] [3] [4] [5] . Overall, onycholysis was reported in 15-25% patients after prolonged weekly paclitaxel treatment, but it was not observed under the standard 3-weekly regimen [1] [2] [3] [4] [5] .
We are currently conducting a study of high dose density chemotherapy in high-risk breast cancer patients. The protocol requires a mobilizing course consisting of epirubicin 150 mg/m 2 , preceded by dexrazoxane (day 1), and paclitaxel 175 mg/m 2 plus filgrastim (day 2); followed by three courses of epirubicin 150 mg/m 2 , preceded by dexrazoxane (day 1), and paclitaxel 400 mg/m 2 (day 2), with peripheral blood progenitor cell support and filgrastim every 16-19 days. Paclitaxel was given as a 6-h infusion in the first 24 evaluable patients (P6h patients), then as a 24-h infusion in the next 15 evaluable patients (P24h patients). The infusion time of paclitaxel 400 mg/m 2 was modified in order to reduce the neurotoxicity of this regimen. Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI-CTC 2.0), which describe two grades of nail changes: discoloration, ridging (koilonychia) or pitting (grade 
